Pemphigoid gestationis: Difference between revisions
From IDWiki
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations") |
No edit summary |
||
Line 1: | Line 1: | ||
− | == |
+ | == Background == |
+ | ===Epidemiology=== |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
+ | |||
⚫ | |||
⚫ | |||
⚫ | |||
[[Category:Dermatology]] |
[[Category:Dermatology]] |
Latest revision as of 22:11, 2 August 2020
Background
Epidemiology
- 1 in 50,000 pregnancies
Clinical Manifestations
- Very itchy bullous or vesicular rash
- Typically starts periumbilically and spreads
- Starts in the second half of pregnancy, may flare post-partum
Diagnosis
- Skin biopsy
Management
- Prednisolone 0.5 mg/kg/d into the postpartum period, then titrate down
- May flare post-partum
- Second-line is azathioprine
Prognosis and Complications
- 10% risk of neonatal pemphigoid
- Associated with other autoimmune disorders